PD, PhD Coordinator Translational Research Unit (TRU)
Senior Teaching and Research Assistant
1998-2001 Bachelors of Science (BSc), Major in
Physiology, McGill University,
2001-2003 Masters of Science (MSc), Department
of Pathology, McGill University,
2003-2007 Doctor of Philosophy (PhD), Jointly
with the Departments of Pathology
and of Mathematics and Statistics,
McGill University, Canada
2010 Venia Docendi (PD), Faculty of
Medicine, University of Basel,
2012 Umhabilitation (PD), Faculty of
Medicine, University of Bern, Switzerland
2007-2010 Postdoctoral Fellow, Institute of
Pathology, University Hospital
2011 present - Senior research and
Our research group performs inter-disciplinary translational research aimed at improving the clinical management of patients with colorectal cancer. We are primarily interested in the molecular classification of colorectal cancers and the clinical relevance of molecular, protein and histomorphological biomarkers as prognostic and predictive features of tumor response to therapies. As such, our group has strengths in histology, immunohistochemistry and tissue microarray construction, molecular analysis, and the development of biostatistical prognostic and predictive models.
Selected recent publications
Zlobec I, Bihl MP, Foerster A, Rufle A, Lugli A.
The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology. 2012 [Epub ahead of print]. Pubmed
Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A.
Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol. 2011; 225(3):336-43. Pubmed
Zlobec I, Molinari F, Kovac M, Bihl MP, Altermatt HJ, Diebold J, Frick H, Germer M, Horcic M, Montani M, Singer G, Yurtsever H, Zettl A, Terracciano L, Mazzucchelli L, Saletti P, Frattini M, Heinimann K, Lugli A.
Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. Br J Cancer. 2010; 102(1):151-61. Pubmed
Zlobec I, Terracciano L, Tornillo L, Günthert U, Vuong T, Jass JR, Lugli A.
Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut. 2008 ; 57(10):1413-9. Pubmed
Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A.
Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol. 2007; 60(10):1112-6. Pubmed
Zlobec I, Steele R, Michel RP, Compton CC, Lugli A, Jass JR.
Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer. Mod Pathol. 2006; 19(9):1236-42. Pubmed
Zlobec I, Steele R, Nigam N, Compton CC.
A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. Clin Cancer Res. 2005; 11(15):5440-3. Pubmed